Abstract: Non-small cell lung cancer (NSCLC) accounts for approximately 85% of clinical lung cancer cases; 53% of patients are at an advanced stage at initial diagnosis. In recent years, immune checkpoint inhibitors (ICIs) have achieved remarkable success in the treatment of late-stage cancer. Radiotherapy is commonly used in the palliative treatment of advanced NSCLC. Studies have shown that combining immunotherapy with radiotherapy in advanced NSCLC improves progression-free survival (PFS) and overall survival (OS) compared with monotherapy and does not increase the incidence of adverse effects above grade Ⅲ. However, the choice of ICIs, the dose and fraction of radiotherapy, and the sequence of combination treatments have not been clarified. This article reviews the clinical research progress of immunotherapy combined with radiotherapy in advanced NSCLC, and provides a reference for clinical practice.